Below are the most recent publications written about "Dexamethasone" by people in Profiles.
-
Suzuki K, Matsumoto M, Takamatsu H, Kosugi H, Kondo T, Fujisaki T, Facon T, Zweegman S, Ito M, Sakai C, Kanai S, Nakatogawa T, Rowe M, Carson R, Usmani SZ. Daratumumab plus VRd in Japanese transplant-ineligible/deferred NDMM patients: Japanese subgroup of the CEPHEUS trial. Int J Hematol. 2026 Jul; 124(1):104-113.
-
Puig N, Leleu X, Lee HC, Davies FE, H?jek R, Hungria V, Thompson MA, Cook G, Ojeda JV, Weisel KC, Berdeja JG, Usmani SZ, Symeonidis A, Nascimento-Ferreira I, Arthur D, Mokr? L, Ren K, Cherepanov D, Terpos E. Comparative Effectiveness and Safety of PI-Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT-MM Data Analysis. Eur J Haematol. 2026 Apr; 116(4):458-470.
-
Sanchez MM, Panagiotakopoulos L, Hayes T, Howell BR, Ethun K, Easley KA, Silvestri G, Carnathan DG, McCandless J, Meyer J, Neigh GN. Long-Term Alterations of Glucocorticoid Receptor Expression and CD4+ T Cells in Adolescent Rhesus Macaques Following Early-Life Adversity. Biomolecules. 2025 12 05; 15(12).
-
Brown J, Milgrim F, Driver L, Meeker MA, Tucker R, Le NN, Nagdev A, Duggan NM, Martin D, Heffler M, Shokoohi H, Dreyfuss A, Fung C, Perice L, Truong N, Jafry SZ, Macias M, Riscinti M, Goldsmith A. Efficacy and Safety of Adjunct Medications in ED Ultrasound-Guided Nerve Blocks: A National Ultrasound-Guided NeRVE (NURVE) Block Registry Study. Acad Emerg Med. 2025 12; 32(12):1299-1308.
-
Rodriguez-Otero P, Voorhees PM, Boccadoro M, Laubach J, Einsele H, Sborov DW, Dimopoulos MA, Broijl A, Mina R, Spencer A, Schjesvold F, Silbermann R, Gay F, Costa LJ, Perrot A, Liu Y, Wang J, Sitthi-Amorn A, Carson R, Cortoos A, Usmani SZ, Richardson PG, Moreau P, Sonneveld P, Kaufman JL. Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged =65 years from GRIFFIN and PERSEUS. Clin Lymphoma Myeloma Leuk. 2025 Oct; 25(10):746-758.e6.
-
Facon T, Moreau P, Weisel K, Goldschmidt H, Usmani SZ, Chari A, Plesner T, Orlowski RZ, Bahlis N, Basu S, Hulin C, Quach H, O'Dwyer M, Perrot A, Jacquet C, Venner CP, Raje N, Tiab M, Macro M, Frenzel L, Leleu X, Cook G, Wang G, Pei H, Krevvata M, Carson R, Borgsten F, Kumar SK. Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes. Leukemia. 2025 04; 39(4):942-950.
-
Weisel K, Mateos MV, Landgren O, Leleu X, Quach H, Bennett L, Talpes M, Majer I, Patel S, Usmani SZ. Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR Trial. Clin Lymphoma Myeloma Leuk. 2025 Aug; 25(8):590-605.
-
Perrot A, Facon T, Plesner T, Usmani SZ, Kumar S, Bahlis NJ, Hulin C, Orlowski RZ, Nahi H, Mollee P, Ramasamy K, Roussel M, Jaccard A, Delforge M, Karlin L, Arnulf B, Chari A, Wang G, Gupta-Werner N, Kaila S, Pei H, Matt K, Gries KS, Carson R, Borgsten F, Weisel K. Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes. Eur J Haematol. 2025 May; 114(5):883-889.
-
Bhutani M, Robinson M, Foureau D, Atrash S, Paul B, Guo F, Grayson JM, Ivanina-Foureau A, Pineda-Roman M, Varga C, Friend R, Ferreri CJ, Begic X, Norek S, Drennan T, Anderson MB, Symanowski JT, Voorhees PM, Usmani SZ. MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma. Blood Adv. 2025 Feb 11; 9(3):507-519.
-
Usmani SZ, Facon T, Hungria V, Bahlis NJ, Venner CP, Braunstein M, Pour L, Mart? JM, Basu S, Cohen YC, Matsumoto M, Suzuki K, Hulin C, Grosicki S, Legiec W, Beksac M, Maiolino A, Takamatsu H, Perrot A, Turgut M, Ahmadi T, Liu W, Wang J, Chastain K, Vermeulen J, Krevvata M, Lopez-Masi L, Carey J, Rowe M, Carson R, Zweegman S. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. Nat Med. 2025 Apr; 31(4):1195-1202.